University of Toronto Advances tRNA Therapy for Genetic Diseases

Researchers at the University of Toronto have developed an engineered transfer RNA (tRNA) approach that could support the treatment of multiple genetic diseases caused by the same type of mutation.

The research focuses on nonsense mutations, which introduce premature stop signals into the genetic instructions used to produce proteins. 

These mutations can prevent cells from making full-length, functional proteins and are linked to thousands of inherited disorders, including certain forms of cystic fibrosis and muscular and neurological diseases.

The team engineered tRNA to recognise premature stop signals and allow protein production to continue. 

This approach could potentially address the same mutation type across different genes and diseases, reducing the need to develop separate therapies for individual genetic mutations.

The study demonstrated that engineered tRNA could suppress disease-causing nonsense mutations and restore full-length protein production in laboratory and preclinical cystic fibrosis models.

Researchers also found that the approach could be combined with existing cystic fibrosis medicines, indicating potential for combination treatment.

The technology remains at an early research stage. However, its ability to target three common premature stop signals could support a broader therapeutic platform for genetic diseases affecting different organs and tissues.